<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03030404</url>
  </required_header>
  <id_info>
    <org_study_id>170043</org_study_id>
    <secondary_id>17-C-0043</secondary_id>
    <nct_id>NCT03030404</nct_id>
  </id_info>
  <brief_title>Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer</brief_title>
  <official_title>Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      Gastric cancers are cancers of the stomach. Hereditary ones are passed from parent to child.&#xD;
      Researchers want to gather data about hereditary gastric cancers. They want to learn about&#xD;
      changes these cause in the body and about the genes involved.&#xD;
&#xD;
      Objective:&#xD;
&#xD;
      -To gather data about hereditary gastric cancer.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  People at least 2 years old with personal or family history with a hereditary gastric&#xD;
           cancer.&#xD;
&#xD;
        -  People at least 2 years old with gene changes that lead to such cancer or a lesion that&#xD;
           may be hereditary.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened in a separate protocol.&#xD;
&#xD;
        -  Participants will have:&#xD;
&#xD;
             -  Physical exam&#xD;
&#xD;
             -  Medical history&#xD;
&#xD;
             -  Blood tests&#xD;
&#xD;
             -  Scans&#xD;
&#xD;
             -  Photos of skin lesions and other findings&#xD;
&#xD;
             -  Gynecology consultation for women&#xD;
&#xD;
             -  Cheek swab (some participants)&#xD;
&#xD;
        -  For some participants, their relatives will be asked to join the study.&#xD;
&#xD;
        -  Some participants will be asked to allow the study to get stored tissue samples for&#xD;
           relatives who have died.&#xD;
&#xD;
        -  Some samples will be sent to outside labs. All personal data will be protected. Samples&#xD;
           will be destroyed when the study ends.&#xD;
&#xD;
        -  Participants will get the results of genetic testing.&#xD;
&#xD;
        -  Participants who cannot come to the NIH clinic may just give a cheek swab and have&#xD;
           genetic testing done.&#xD;
&#xD;
        -  Some participants will be contacted for more testing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      An estimated 1-3% of gastric cancer cases occur within a familial background as part of an&#xD;
      inherited cancer syndrome.&#xD;
&#xD;
      Hereditary Diffuse Gastric Cancer (HDGC) is the most frequent form of familial gastric cancer&#xD;
      and has been linked to a germline mutation in the CDH1 gene.&#xD;
&#xD;
      Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) is a more recently&#xD;
      described autosomal dominant syndrome characterized by fundic gland polyposis with antral&#xD;
      sparing.&#xD;
&#xD;
      Other germline mutations that predispose to gastric cancer such as SDH (succinate&#xD;
      dehydrogenase protein subunits) gene and CTNNA1 (alpha catenin).&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      Characterize the natural and clinical histories of hereditary gastric cancer syndromes.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Individuals, and family members, who fulfill clinical criteria for a hereditary gastric&#xD;
      cancer syndrome irrespective of previous genetic testing or treatment.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      These rare families will be recruited to genetically confirm diagnosis and study the natural&#xD;
      history of hereditary gastric cancers.&#xD;
&#xD;
      Genetic testing will be offered to gain appreciation of the effect of mutations on the&#xD;
      relative activity of various germline and somatic mutations.&#xD;
&#xD;
      We will determine if there is a relationship between mutation and disease phenotype.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 27, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of the natural and clinical histories of hereditary gastric cancer syndromes</measure>
    <time_frame>10 years</time_frame>
    <description>Characterization of the natural and clinical histories of hereditary gastric cancer syndromes</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1150</enrollment>
  <condition>Stomach Neoplasms</condition>
  <condition>Stomach Cancer</condition>
  <condition>Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS)</condition>
  <condition>Hereditary Diffuse Gastric Cancer (HDGC)</condition>
  <condition>Familial Diffuse Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Subjects with suspicious personal or family medical history of gastric cancer or gastric cancer syndrome.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals, and family members, who fulfill clinical criteria for a hereditary gastric&#xD;
        cancer syndrome irrespective of previous genetic testing or treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        -INCLUSION CRITERIA:&#xD;
&#xD;
          1. An individual, or their family members, with any of the following:&#xD;
&#xD;
               -  Fulfills clinical criteria for Hereditary Diffuse Gastric Cancer (HGDC) syndrome&#xD;
                  or Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS) syndrome&#xD;
&#xD;
               -  Clinically suspicious personal or family medical history of gastric cancer or&#xD;
                  gastric cancer syndrome that warrants genetics evaluation&#xD;
&#xD;
               -  Current diagnosis of gastric cancer and a germline mutation associated with a&#xD;
                  known cancer syndrome or an associated family history of gastric cancer&#xD;
&#xD;
               -  Harbors a pathogenic germline mutation known to predispose to gastric cancer&#xD;
&#xD;
               -  First-degree relatives, regardless of family history or personal history of&#xD;
                  cancer, with a documented deleterious germline mutation (including but not&#xD;
                  limited to CDH1, CTNNA1, SDH) known to predispose to gastric tumors&#xD;
&#xD;
               -  Diagnosis or suspicion of a premalignant or malignant stomach lesion of suspected&#xD;
                  hereditary etiology&#xD;
&#xD;
          2. Age greater than or equal to 18 years; patients under 18 years of age and greater than&#xD;
             or equal to the age of 2 may participate if the tissue acquisition is performed during&#xD;
             a clinically indicated surgical procedure, and the sampling of tissue, blood and urine&#xD;
             collection does not add risk to the clinically indicated procedures.&#xD;
&#xD;
          3. Ability of subject or legally authorized representative (LAR) to understand and the&#xD;
             willingness to sign a written informed consent document.&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        -None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremy L Davis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monica E Epstein, R.N.</last_name>
    <phone>(240) 281-4207</phone>
    <email>foregut@mail.nih.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>For more information at the NIH Clinical Center contact National Cancer Institute Referral Office</last_name>
      <phone>888-624-1937</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2017-C-0043.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>Hansford S, Kaurah P, Li-Chang H, Woo M, Senz J, Pinheiro H, Schrader KA, Schaeffer DF, Shumansky K, Zogopoulos G, Santos TA, Claro I, Carvalho J, Nielsen C, Padilla S, Lum A, Talhouk A, Baker-Lange K, Richardson S, Lewis I, Lindor NM, Pennell E, MacMillan A, Fernandez B, Keller G, Lynch H, Shah SP, Guilford P, Gallinger S, Corso G, Roviello F, Caldas C, Oliveira C, Pharoah PD, Huntsman DG. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015 Apr;1(1):23-32. doi: 10.1001/jamaoncol.2014.168. Erratum in: JAMA Oncol. 2015 Apr;1(1):110.</citation>
    <PMID>26182300</PMID>
  </reference>
  <reference>
    <citation>Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C; International Gastric Cancer Linkage Consortium. Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. J Med Genet. 2010 Jul;47(7):436-44. doi: 10.1136/jmg.2009.074237. Erratum in: J Med Genet. 2011 Mar;48(3):216. Van Krieken, Nicola [corrected to Van Grieken, Nicola C].</citation>
    <PMID>20591882</PMID>
  </reference>
  <reference>
    <citation>van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, Caldas C, Schreiber KE, Hardwick RH, Ausems MG, Bardram L, Benusiglio PR, Bisseling TM, Blair V, Bleiker E, Boussioutas A, Cats A, Coit D, DeGregorio L, Figueiredo J, Ford JM, Heijkoop E, Hermens R, Humar B, Kaurah P, Keller G, Lai J, Ligtenberg MJ, O'Donovan M, Oliveira C, Pinheiro H, Ragunath K, Rasenberg E, Richardson S, Roviello F, Schackert H, Seruca R, Taylor A, Ter Huurne A, Tischkowitz M, Joe ST, van Dijck B, van Grieken NC, van Hillegersberg R, van Sandick JW, Vehof R, van Krieken JH, Fitzgerald RC. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015 Jun;52(6):361-74. doi: 10.1136/jmedgenet-2015-103094. Epub 2015 May 15. Review.</citation>
    <PMID>25979631</PMID>
  </reference>
  <verification_date>October 25, 2021</verification_date>
  <study_first_submitted>January 24, 2017</study_first_submitted>
  <study_first_submitted_qc>January 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2017</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Genetics and Germline Mutations</keyword>
  <keyword>Familial Background</keyword>
  <keyword>Inherited Cancer Syndrome</keyword>
  <keyword>Germline Mutation in the CDH1 Gene</keyword>
  <keyword>Lobular Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Disease Susceptibility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

